on Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma Reveals Promising Data for HDP-101 at ADC Congress 2025
Heidelberg Pharma AG has announced new clinical data for their leading Amanitin-based ADC candidate, HDP-101, at the World ADC Congress 2025 in San Diego. This data from the ongoing Phase I/IIa trial highlights the encouraging anti-tumor activity and safety profile of HDP-101 in treating relapsed or refractory multiple myeloma. The drug targets anti-BCMA, addressing significant needs in bone marrow cancer therapy.
Phase I results are focused on determining optimal dosage levels. CEO Professor Andreas Pahl will update on this at the congress on November 5. A subsequent R&D webinar on November 11, featuring Professor Marc-Steffen Raab, will allow interaction with investors and analysts about HDP-101's potential and future directional strategies.
Heidelberg Pharma's effort is part of a broader focus on developing innovative ADC technologies to treat cancer. The company remains committed to advancing its clinical programs and exploring strategic partnerships for future growth.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news